Trademark: 97461217
Status Date
Wednesday, March 20, 2024
Filing Date
Thursday, June 16, 2022
Published for Opposition
Tuesday, April 23, 2024
5 Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy
42 Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
CTX THREE ONE ZERO; CTX THREE HUNDRED TEN
Apr 3, 2024
Notification Of Notice Of Publication E-Mailed
Mar 16, 2024
Approved For Pub - Principal Register
Feb 27, 2024
Teas/Email Correspondence Entered
Feb 27, 2024
Correspondence Received In Law Office
Feb 27, 2024
Teas Request For Reconsideration Received
Dec 18, 2023
Application Extension Granted/Receipt Provided
Dec 18, 2023
Application Extension To Response Period - Received
Oct 2, 2023
Notification Of Final Refusal Emailed
Oct 2, 2023
Final Refusal E-Mailed
Oct 2, 2023
Final Refusal Written
Aug 11, 2023
Teas/Email Correspondence Entered
Aug 10, 2023
Correspondence Received In Law Office
Aug 10, 2023
Teas Response To Office Action Received
Jul 3, 2023
Assigned To Examiner
May 11, 2023
Application Extension Granted/Receipt Provided
May 11, 2023
Application Extension To Response Period - Received
Feb 14, 2023
Notification Of Non-Final Action E-Mailed
Feb 14, 2023
Non-Final Action E-Mailed
Feb 14, 2023
Non-Final Action Written
Feb 7, 2023
Assigned To Examiner
Jun 30, 2022
New Application Office Supplied Data Entered
Jun 20, 2022
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
